Skip to main content

Table 3 The Cox proportional hazards model of progression-free survival in synchronous and metachronous mRCC group

From: Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis

 

Synchronous mRCC (N = 144 /EVENT = 130)

Metachronous mRCC (N = 70/EVENT = 63)

Univariable

Multivariable

Univariable

Multivariable

Hazard ratio

(95% CI)

P-value

Hazard ratio

(95% CI)

P-value

Hazard ratio

(95% CI)

P-value

Hazard ratio

(95% CI)

P-value

Risk group

Intermediate

1

   

1

   

poor

1.728 (1.156–2.584)

0.0077

  

1.801 (0.766–4.235)

0.1772

  

Therapy

IT

1

 

1

 

1

 

1

 

TT

1.858 (1.288–2.681)

0.0009

1.696 (1.157–2.486)

0.0068

2.019 (1.202–3.39)

0.0079

2.019 (1.202–3.39)

0.0079

Treatment Free interval

≥1 yr

1

   

1

   

< 1 yr

1.017 (0.473–2.184)

0.9660

  

1.752 (0.995–3.084)

0.052

  

Gender

Male

1

   

1

   

Female

1.215 (0.777–1.901)

0.3934

  

1.155 (0.670–1.993)

0.6041

  

Age (year)

 

0.991 (0.975–1.007)

0.2801

  

0.980 (0.951–1.009)

0.1692

  

Anemia

Normal

1

   

1

   

Hb < 13.5(male)/12.0(Female)

1.724 (1.142–2.600)

0.0095

  

0.846 (0.427–1.675)

0.6311

  

Hypercalcemia

Normal

1

   

1

   

> 10 mg/dL or 2.5 mmol/L

1.166 (0.705–1.929)

0.5499

  

0.995 (0.444–2.227)

0.9897

  

Neutrophilia

Normal

1

 

1

 

1

   

< 1500 or > 7500

2.497 (1.53–4.074)

0.0002

2.105 (1.274–3.478)

0.0037

0.918 (0.464–1.817)

0.806

  

Elevated LDH

Normal

1

   

1

   

1.5 X ULN

1.482 (0.943–2.329)

0.0883

  

1.491 (0.661–3.365)

0.3357

  

KPS

>  80

1

       

≤ 80

2.122 (0.779–5.779)

0.1409

      

Thrombocytosis

Normal

1

   

1

   

> 400 K

1.700 (1.013–2.855)

0.0448

  

1.054 (0.379–2.932)

0.9199